Brooklyn Financial Statements From 2010 to 2022

BTX -  USA Stock  

USD 0.57  0.03  5.00%

Brooklyn Immunotherapeuti financial statements provide useful quarterly and yearly information to potential Brooklyn Immunotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Brooklyn Immunotherapeuti financial statements helps investors assess Brooklyn Immunotherapeuti's valuation, profitability, and current liquidity needs.
We have found one hundred five available fundamental signals for Brooklyn Immunotherapeutics, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate all of Brooklyn Immunotherapeutics prevailing market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Brooklyn Immunotherapeuti Revenue Per Employee is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Revenue Per Employee of 38,075.35 in 2021. Average Assets is likely to rise to about 42.4 M in 2022, whereas Net Income Per Employee is likely to drop (464.6 K) in 2022.
  
Refresh
Check Brooklyn Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brooklyn main balance sheet or income statement drivers, such as Direct Expenses of 541.5 K, Cost of Revenue of 9.2 M or Gross Profit of 12.2 M, as well as many exotic indicators such as Long Term Debt to Equity of 3.0E-4, PPandE Turnover of 1.03 or Receivables Turnover of 11.02. Brooklyn financial statements analysis is a perfect complement when working with Brooklyn Immunotherapeuti Valuation or Volatility modules. It can also supplement various Brooklyn Immunotherapeuti Technical models. Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors.

Brooklyn Immunotherapeuti Revenues

19.16 Million

Share

Brooklyn Immunotherapeuti Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.9 M32.4 M17.3 M
Increasing
Slightly volatile
Cash and Equivalents18.3 M17 M5.6 M
Increasing
Slightly volatile
Investments1.2 M1.1 M410.8 K
Increasing
Slightly volatile
Investments Non Current1.2 M1.1 M410.8 K
Increasing
Slightly volatile
Deferred Revenue545.3 K531.3 K1.2 M
Decreasing
Stable
Property Plant and Equipment Net3.3 M3.2 M3.7 M
Decreasing
Stable
Trade and Non Trade Receivables979.9 K786.6 K945.4 K
Increasing
Very volatile
Trade and Non Trade Payables1.9 M1.8 M742.5 K
Increasing
Slightly volatile
Goodwill and Intangible Assets2.1 M1.8 M2.7 M
Decreasing
Slightly volatile
Total Liabilities20.6 M25.9 M12.2 M
Increasing
Slightly volatile
Shareholders Equity5.5 M6.5 M5.1 M
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income305.1 K241.2 K411.1 K
Decreasing
Slightly volatile
Current Assets20.2 M18.8 M8.9 M
Increasing
Slightly volatile
Assets Non Current12.2 M13.7 M8.9 M
Increasing
Slightly volatile
Current LiabilitiesM3.7 M5.1 M
Increasing
Very volatile
Liabilities Non Current24 M22.2 M7.7 M
Increasing
Slightly volatile
Tax Liabilities171.9 K120.6 K275.8 K
Decreasing
Slightly volatile
Total Debt3.8 M2.7 M3.8 M
Increasing
Slightly volatile
Debt Current437.2 K426 K1.5 M
Increasing
Stable
Debt Non Current2.6 M2.3 M2.3 M
Increasing
Slightly volatile
Shareholders Equity USD5.5 M6.5 M5.1 M
Decreasing
Slightly volatile
Cash and Equivalents USD18.3 M17 M5.6 M
Increasing
Slightly volatile
Total Debt USD3.8 M2.7 M3.8 M
Increasing
Slightly volatile
Accounts Payable2.1 M2.3 M2.1 M
Increasing
Stable
Receivables4.7 K4.6 K931.3 K
Decreasing
Slightly volatile
Inventories92490046.5 K
Decreasing
Slightly volatile

Brooklyn Immunotherapeuti Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues19.2 M17.8 M22.3 M
Decreasing
Slightly volatile
Cost of Revenue9.2 M8.6 MM
Increasing
Stable
Selling General and Administrative Expense14.2 M14.7 M15.7 M
Decreasing
Slightly volatile
Research and Development Expense11.5 M12.7 M5.2 M
Increasing
Slightly volatile
Operating Expenses113.3 M105 M31.1 M
Increasing
Slightly volatile
Interest Expense314.2 K286.4 K264.8 K
Increasing
Slightly volatile
Income Tax Expense4.6 K4.5 K35.9 K
Decreasing
Slightly volatile
Preferred Dividends Income Statement Impact14.3 K14.4 K15.7 K
Decreasing
Slightly volatile
Weighted Average Shares46.7 M43.3 MM
Increasing
Slightly volatile
Weighted Average Shares Diluted46.7 M43.3 MM
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(125.5 M)(122.3 M)(23 M)
Decreasing
Slightly volatile
Revenues USD19.2 M17.8 M22.3 M
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(125.5 M)(122.3 M)(23 M)
Decreasing
Slightly volatile
Gross Profit12.2 M11.1 M14.6 M
Decreasing
Slightly volatile
Operating Income(107.7 M)(105 M)(18.9 M)
Decreasing
Slightly volatile
Direct Expenses541.5 K442.8 K511.4 K
Decreasing
Stable

Brooklyn Immunotherapeuti Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals119.9 K120.6 K131.9 K
Decreasing
Slightly volatile
Net Cash Flow from Financing66.4 M61.6 M11.6 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (966.8 K)(942 K)(50.8 K)
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares67.5 M62.5 M12.2 M
Increasing
Slightly volatile
Net Cash Flow from Operations(24.1 M)(23.5 M)(4.3 M)
Decreasing
Slightly volatile
Effect of Exchange Rate Changes on Cash 52.1 K48.3 K(6.4 K)
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents16.6 M15.4 MM
Increasing
Slightly volatile
Share Based Compensation5.6 M5.2 M1.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion471.1 K459 K2.3 M
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(9.98)(9.727)(0.319)
Decreasing
Very volatile
Return on Invested Capital(12.04)(11.729)(2.5272)
Decreasing
Slightly volatile
Gross Margin0.570.560.6427
Decreasing
Slightly volatile
EBITDA Margin0.08810.08160.0369
Increasing
Slightly volatile
Return on Sales(0.11)(0.1)(0.1015)
Increasing
Stable
Asset Turnover1.261.171.4905
Decreasing
Slightly volatile
Enterprise Value over EBITDA(1.65)(1.608)41.1325
Decreasing
Slightly volatile
Enterprise Value over EBIT(2.36)(2.3)(1.3583)
Increasing
Stable
Sales per Share17.5612.424.5433
Decreasing
Slightly volatile
Price to Sales Ratio0.290.290.6548
Decreasing
Slightly volatile
Price to Book Value36.0133.3787.4374
Increasing
Slightly volatile
Debt to Equity Ratio4.33.9881.6443
Increasing
Slightly volatile
Current Ratio5.515.1041.9319
Increasing
Slightly volatile
Free Cash Flow per Share(0.59)(0.546)(2.0772)
Increasing
Slightly volatile
Book Value per Share0.150.156.0807
Decreasing
Slightly volatile
Tangible Assets Book Value per Share0.720.70210.8194
Decreasing
Slightly volatile
Total Assets Per Share1.00.810.9734
Decreasing
Stable
Receivables Turnover11.0210.215.9969
Increasing
Slightly volatile
Inventory Turnover9.799.5420.4363
Decreasing
Slightly volatile
PPandE Turnover1.031.02.0928
Decreasing
Slightly volatile
Cash and Equivalents Turnover0.10.09950.2289
Decreasing
Slightly volatile
Accounts Payable Turnover0.850.832.3608
Decreasing
Slightly volatile
Accrued Expenses Turnover0.670.651.4715
Decreasing
Slightly volatile
Long Term Debt to Equity3.0E-43.0E-40.0227
Decreasing
Stable
Quick Ratio4.384.824.2468
Increasing
Stable
Net Current Assets as percentage of Total Assets37.5338.631.0086
Decreasing
Very volatile
Revenue to Assets0.020.01950.0548
Decreasing
Slightly volatile

Brooklyn Immunotherapeuti Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(125 M)(121.8 M)(20.7 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(125 M)(121.8 M)(20.7 M)
Decreasing
Slightly volatile
Market Capitalization234.2 M217 M49.7 M
Increasing
Slightly volatile
Enterprise Value211.3 M195.9 M46.4 M
Increasing
Slightly volatile
Invested Capital11.4 M12.4 M8.2 M
Increasing
Slightly volatile
Average Equity13.6 M12.6 M7.2 M
Increasing
Very volatile
Average Assets42.4 M39.3 M18.8 M
Increasing
Slightly volatile
Invested Capital Average9.8 M10.4 M7.2 M
Increasing
Slightly volatile
Tangible Asset Value24.3 M30.4 M14.6 M
Increasing
Slightly volatile
Free Cash Flow(24.3 M)(23.6 M)(5.9 M)
Decreasing
Slightly volatile
Working Capital16.3 M15.1 M3.9 M
Increasing
Slightly volatile
Revenue Per Employee52.4 K38.1 K54.2 K
Decreasing
Slightly volatile
Net Income Per Employee(464.6 K)(430.6 K)(296.9 K)
Decreasing
Stable

Brooklyn Fundamental Market Drivers

Short Percent Of Float5.42%
Forward Price Earnings-1.05
Shares Short Prior Month2.3M
Average Daily Volume Last 10 Day745.36k
Average Daily Volume In Three Month559.59k
Date Short Interest29th of April 2022
Fifty Day Average0.9160
Two Hundred Day Average4.4167

Brooklyn Upcoming Events

Upcoming Quarterly Report10th of March 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Brooklyn Immunotherapeuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti income statement, its balance sheet, and the statement of cash flows. Brooklyn Immunotherapeuti investors use historical funamental indicators, such as Brooklyn Immunotherapeuti's revenue or net income, to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brooklyn Immunotherapeuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brooklyn Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue531.3 K545.3 K
Cost of Revenue8.6 M9.2 M
Revenues17.8 M19.2 M
Revenue to Assets 0.0195  0.02 
Revenue Per Employee38.1 K52.4 K
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
30.2 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.